Search
Pexastimogene devacirepvec
go.drugbank.com/drugs/DB15069InvestigationalPexastimogene devacirepvec is under investigation in clinical trial NCT00429312 (A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma).
H3B-6527
go.drugbank.com/drugs/DB15169InvestigationalH3B-6527 is under investigation in clinical trial NCT03424577 (A Study to Evaluate the Food-Effect of H3B-6527).
ReN001
go.drugbank.com/drugs/DB05236InvestigationalReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food and Drug Administration in the United States for consideration for the treatment of stroke in humans
Deracoxib
go.drugbank.com/drugs/DB11395ExperimentalVet approvedIt is sold in tablets, which have added beefy flavour to increase palatability. … Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to treat osteoarthritis in dogs.
V591
go.drugbank.com/drugs/DB16438InvestigationalThrough Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and accelerate the development of V591 to phase I clinical trials (NCT04498247)[L30593].
PMI-001
go.drugbank.com/drugs/DB05730ExperimentalPMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc.
1D-myo-inositol 1,4,5-trisphosphate
go.drugbank.com/drugs/DB03401ExperimentalIntracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane.
Dexchlorpheniramine
go.drugbank.com/drugs/DB13679InvestigationalIt disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells.
Cilobradine
go.drugbank.com/drugs/DB20039InvestigationalCilobradine is under investigation in clinical trial NCT02264041 (Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine).
Enlonstobart
go.drugbank.com/drugs/DB21890Investigational[A274486] It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.